Dacetuzumab Explained

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]

This drug was developed by Seattle Genetics, Inc.

Notes and References

  1. http://www.ama-assn.org/ama1/pub/upload/mm/365/dacetuzumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab
  2. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG . 6 . Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma . Journal of Clinical Oncology . 27 . 26 . 4371–7 . September 2009 . 19636010 . 10.1200/JCO.2008.21.3017 . free .
  3. Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ . Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies . Current Opinion in Investigational Drugs . 10 . 6 . 579–87 . June 2009 . 19513947 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dacetuzumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.